These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 22033197)
1. Case study: adapting in vitro blood-brain barrier models for use in early-stage drug discovery. Vandenhaute E; Sevin E; Hallier-Vanuxeem D; Dehouck MP; Cecchelli R Drug Discov Today; 2012 Apr; 17(7-8):285-90. PubMed ID: 22033197 [TBL] [Abstract][Full Text] [Related]
2. Models for predicting blood-brain barrier permeation. Nielsen PA; Andersson O; Hansen SH; Simonsen KB; Andersson G Drug Discov Today; 2011 Jun; 16(11-12):472-5. PubMed ID: 21513815 [TBL] [Abstract][Full Text] [Related]
3. In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery. Lacombe O; Videau O; Chevillon D; Guyot AC; Contreras C; Blondel S; Nicolas L; Ghettas A; Bénech H; Thevenot E; Pruvost A; Bolze S; Krzaczkowski L; Prévost C; Mabondzo A Mol Pharm; 2011 Jun; 8(3):651-63. PubMed ID: 21438632 [TBL] [Abstract][Full Text] [Related]
4. Analysing molecular polar surface descriptors to predict blood-brain barrier permeation. Shityakov S; Neuhaus W; Dandekar T; Förster C Int J Comput Biol Drug Des; 2013; 6(1-2):146-56. PubMed ID: 23428480 [TBL] [Abstract][Full Text] [Related]
5. Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes. Shawahna R; Decleves X; Scherrmann JM Curr Drug Metab; 2013 Jan; 14(1):120-36. PubMed ID: 23215812 [TBL] [Abstract][Full Text] [Related]
6. Current in vitro and in silico models of blood-brain barrier penetration: a practical view. Vastag M; Keseru GM Curr Opin Drug Discov Devel; 2009 Jan; 12(1):115-24. PubMed ID: 19152220 [TBL] [Abstract][Full Text] [Related]
7. Porcine brain microvessel endothelial cells as an in vitro model to predict in vivo blood-brain barrier permeability. Zhang Y; Li CS; Ye Y; Johnson K; Poe J; Johnson S; Bobrowski W; Garrido R; Madhu C Drug Metab Dispos; 2006 Nov; 34(11):1935-43. PubMed ID: 16896068 [TBL] [Abstract][Full Text] [Related]
8. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept. Reichel A Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839 [TBL] [Abstract][Full Text] [Related]
9. Methods to assess drug permeability across the blood-brain barrier. Nicolazzo JA; Charman SA; Charman WN J Pharm Pharmacol; 2006 Mar; 58(3):281-93. PubMed ID: 16536894 [TBL] [Abstract][Full Text] [Related]
10. In vitro models of the blood-brain barrier for the study of drug delivery to the brain. Wilhelm I; Krizbai IA Mol Pharm; 2014 Jul; 11(7):1949-63. PubMed ID: 24641309 [TBL] [Abstract][Full Text] [Related]
11. Strategies to optimize brain penetration in drug discovery. Liu X; Chen C Curr Opin Drug Discov Devel; 2005 Jul; 8(4):505-12. PubMed ID: 16022187 [TBL] [Abstract][Full Text] [Related]
12. Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain. Pardridge WM Curr Opin Drug Discov Devel; 2003 Sep; 6(5):683-91. PubMed ID: 14579518 [TBL] [Abstract][Full Text] [Related]
13. Building predictive ADMET models for early decisions in drug discovery. Penzotti JE; Landrum GA; Putta S Curr Opin Drug Discov Devel; 2004 Jan; 7(1):49-61. PubMed ID: 14982148 [TBL] [Abstract][Full Text] [Related]
14. Ionization-specific QSAR models of blood-brain penetration of drugs. Lanevskij K; Japertas P; Didziapetris R; Petrauskas A Chem Biodivers; 2009 Nov; 6(11):2050-4. PubMed ID: 19937840 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability. Mensch J; Melis A; Mackie C; Verreck G; Brewster ME; Augustijns P Eur J Pharm Biopharm; 2010 Mar; 74(3):495-502. PubMed ID: 20067834 [TBL] [Abstract][Full Text] [Related]
16. Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration. Cole S; Bagal S; El-Kattan A; Fenner K; Hay T; Kempshall S; Lunn G; Varma M; Stupple P; Speed W Xenobiotica; 2012 Jan; 42(1):11-27. PubMed ID: 21970687 [TBL] [Abstract][Full Text] [Related]
17. An in vitro transport model for rapid screening and predicting the permeability of candidate compounds at blood-brain barrier. Yang ZH; Sun X; Mei C; Sun XB; Liu XD; Chang Q J Asian Nat Prod Res; 2011 Dec; 13(12):1087-97. PubMed ID: 22115032 [TBL] [Abstract][Full Text] [Related]
18. Insights for predicting blood-brain barrier penetration of CNS targeted molecules using QSPR approaches. Fan Y; Unwalla R; Denny RA; Di L; Kerns EH; Diller DJ; Humblet C J Chem Inf Model; 2010 Jun; 50(6):1123-33. PubMed ID: 20578728 [TBL] [Abstract][Full Text] [Related]
19. Mimicking brain tissue binding in an in vitro model of the blood-brain barrier illustrates differences between in vitro and in vivo methods for assessing the rate of brain penetration. Heymans M; Sevin E; Gosselet F; Lundquist S; Culot M Eur J Pharm Biopharm; 2018 Jun; 127():453-461. PubMed ID: 29602020 [TBL] [Abstract][Full Text] [Related]
20. How well can in vitro brain microcapillary endothelial cell models predict rodent in vivo blood-brain barrier permeability? Avdeef A Eur J Pharm Sci; 2011 Jun; 43(3):109-24. PubMed ID: 21514381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]